OOIR: Observatory of International Research

Papers

(The median citation count of Neurology-Neuroimmunology & Neuroinflammation is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	467
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	140
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	135
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	114
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	111
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	101
Antibody-Negative Autoimmune Encephalitis	100
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	91
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	82
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	80
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	77
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	75
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	66
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	66
Encephalitis and Myelitis in a Young Woman	64
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	63
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	63
Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway	62
Autoimmune Global Amnesia as Manifestation of AMPAR Encephalitis and Neuropathologic Findings	60
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	56
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	56
Should We Measure CSF Complement Levels in Patients With MOGAD?	54
Acute Paresthesia and Ataxia in a Child	54
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	53
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	53

Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	49
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	48
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	47
Toward Precision Phenotyping of Multiple Sclerosis	44
Treatment With Erythropoietin for Patients With Optic Neuritis	43
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis	43
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	42
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	42
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	42
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	42
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis	41
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	41
Retinal Optical Coherence Tomography in Neuromyelitis Optica	40
Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals	40
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	40
Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls	40
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	40
Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice	40
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	39
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	39
Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy	39
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	39
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	39
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	38
Pediatric MOG-Ab–Associated Encephalitis	38
Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	38
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	38
Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy	37
Acknowledgment to Reviewers	37
“Will the Real Demyelinating Disorder Please Stand Up?”	36
Absence of Systemic Oxidative Stress and Increased CSF Prostaglandin F2α in Progressive MS	36
A 42-Year-Old Woman With Rapidly Expanding White Matter Lesions	36
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease	35
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	35
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	34
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab	34
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis	34
Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients	34
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy	34
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	34
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies	34
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	33
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	32
Recovery From COVID-19 in Multiple Sclerosis	32
Neurologic Manifestations of Common Variable Immunodeficiency	32
B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis	31
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient	31
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies	31
Chronic Dengue Virus Encephalitis	31
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models	30

Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis	30
Cryptococcal Meningitis Reported With Fingolimod Treatment	30
Anti-Adenylate Kinase 5 Encephalitis With Histologic Evidence of CNS Vasculitis	30
Ten Years of Neurology ® Neuroimmunology & Neuroinflammation	29
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis	29
Distinguishing Transient From Persistent Brain Structural Changes in Pediatric Patients With Acute Disseminated Encephalomyelitis	29
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis	29
Chronic Active Lesions and Larger Choroid Plexus Explain Cognition and Fatigue in Multiple Sclerosis	28
Clinical Characterization and Ancillary Tests in Susac Syndrome	28
Potential Role of CHI3L1+ Astrocytes in Progression in MS	28
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis	28
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	28
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis	28
Progressive Encephalomyelopathy in an Older Man	27
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	27
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments	27
PET Study of Microglial Activation in Kleine-Levin Syndrome	27
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	27
Neuropsychological Testing in Autoimmune Encephalitis	26
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	26
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	26
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis	26
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	26
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	26
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	26
Pediatric MOG-Ab–Associated Encephalitis	26
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	25
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	25
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	25
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	25
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	25
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	24
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	24
Cerebellar Ataxia With Anti-DNER Antibodies	24
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	24
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	24
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	24
Progressive Myelitis in a 63-Year-Old Woman	24
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	24
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	24
CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells	24
Ravulizumab and Efgartigimod in Myasthenia Gravis	23
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders	23
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	23
A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement	23
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	23
Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis	22
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	22
Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation	22
Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years	21
Neuromyelitis Optica Spectrum Disorders in Africa	21
Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade	21
Antibody Investigations in 2,750 Children With Suspected Autoimmune Encephalitis	21
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure	21
Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome	21
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	20
Single-Cell Multi-Omics Map of Cell Type–Specific Mechanistic Drivers of Multiple Sclerosis Lesions	20
Inflammatory Activity After Diverse Fertility Treatments	20
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	20
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy	20
Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis	20
Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli	20
Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS	19
Neurology Neuroimmunology & Neuroinflammation 's Acknowledgment to Reviewers	19
Pembrolizumab-Associated CD8 ⁺ Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma	19
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	19
Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate	19
Human Leukocyte Antigen Association Study Reveals DRB104:02 Effects Additional to DRB107:01 in Anti-LGI1 Encephalitis	19
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease	19
COVID-19 Severity in Multiple Sclerosis	19
B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis	19
Comparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With Onchocerca volvulus	19
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	19
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis	19
Autopsy Case of Meningoencephalomyelitis Associated With Glial Fibrillary Acidic Protein Antibody	18
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	18
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis	18
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage	18
Primary Angiitis of the CNS	18
The Calm Between Storms	18

Reemerging Infectious Diseases and Neuroimmunologic Complications	18
Microglia as Central Protagonists in the Chronic Stress Response	18
Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease	18
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	18
Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders	17
Primary Angiitis of the CNS	17
Cardiac Involvement in Neurosarcoidosis	17
Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders	17
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis	17
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration	17
Antibodies Against Glutamic Acid Decarboxylase 65 Are Locally Produced in the CSF and Arise During Affinity Maturation	17
Intrathecal CD8 ⁺ CD20 ⁺ T Cells in Primary Progressive Multiple Sclerosis	16
SARS-CoV-2 Vaccines and Multiple Sclerosis	16
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis	16
Multiple Sclerosis	16
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension	16
Modern Look at Transverse Myelitis and Inflammatory Myelopathy	16
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	16
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies	16
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases	16
Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy	16
Retrospective Pediatric Cohort Study Validates NEOS Score and Demonstrates Applicability in Children With Anti-NMDAR Encephalitis	16
Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates	15
Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice	15
Neurology® Neuroimmunology & Neuroinflammation Acknowledgment to Reviewers	15
MOG Antibody–Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use	15
CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage	15
Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis	15
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology	15
Prolonged Corticosteroids Without Maintenance Immunotherapy for Treatment of Anti-LGI1 Encephalitis	15
Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus	15
Electrolyte Imbalance in Anti LGI1 Encephalitis	15
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis	14
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	14
Acknowledgment to Reviewers	14
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography	14
CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis	14
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	14
Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction	14
Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS	14
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder	14
Isolated Memory Loss in Anti-NMDAR Encephalitis	14
Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis	14
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis	14
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis	14
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab	13
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	13
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	13
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis	13
Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone	13
Multiple Sclerosis, Disease-Modifying Therapies, and Infections	13
Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy	13
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series	13
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab	13
Risk of Getting COVID-19 in People With Multiple Sclerosis	13
Acute Optic Neuropathy in Older Adults	12
Relapsing White Matter Disease and Subclinical Optic Neuropathy	12
Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis	12
Neuroprotective Properties of 4-Aminopyridine	12
Late-Onset Anti-GABA _B Receptor Encephalitis	12
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder	12
Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion	12
Alterations of Thymus-Derived Tregs in Multiple Sclerosis	12
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis	12
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis	12
Therapies in Stiff-Person Syndrome	12
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis	12
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease	12
White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity	12
Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis	12
Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar Syndrome	11
Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion	11
GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder	11
Trajectories of Inflammatory Markers and Post–COVID-19 Cognitive Symptoms	11
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis	11
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome	11
Pachymeningitis in Biopsy-Proven Sarcoidosis	11
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD	11
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis	11
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	11
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	11
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	11
Post-COVID Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy	11
Serum Contactin-1 in CIDP	11
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease	11
CNS Inflammation as the First Sign of Complement Factor I Deficiency	10
Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy	10
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis	10
Defining the Clinicoradiologic Syndrome of SARS-CoV-2 Acute Necrotizing Encephalopathy	10
Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey	10
Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia	10
Structural Changes of Cutaneous Immune Cells in Patients With Type 1 Diabetes and Their Relationship With Diabetic Polyneuropathy	10
Autoimmune Encephalitis Resembling Dementia Syndromes	10
Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease	10
Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature	10